Edap Tms (NASDAQ:EDAP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Monday.

According to Zacks, “EDAP TMS S.A. develops, produces, markets and distributes minimally invasive medical devices, primarily for the treatment of urological diseases. They currently produce and market devices for treatment of benign prostate hyperplasia and urinary tract stones. They are also developing a third range of products for minimally invasive destruction of certain types of tumors. “

Other equities research analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $6.50 price objective on shares of Edap Tms in a report on Monday, July 2nd. TheStreet upgraded shares of Edap Tms from a “d+” rating to a “c” rating in a report on Tuesday, June 26th. Finally, ValuEngine upgraded shares of Edap Tms from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd.

Shares of EDAP opened at $2.98 on Monday. The stock has a market capitalization of $82.64 million, a price-to-earnings ratio of -298.00 and a beta of 0.53. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.04 and a current ratio of 2.45. Edap Tms has a fifty-two week low of $2.07 and a fifty-two week high of $4.25.

Edap Tms (NASDAQ:EDAP) last announced its quarterly earnings data on Wednesday, August 29th. The medical equipment provider reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01). The business had revenue of $10.14 million during the quarter, compared to analysts’ expectations of $10.74 million. Edap Tms had a negative return on equity of 4.04% and a negative net margin of 3.55%. equities analysts predict that Edap Tms will post -0.03 earnings per share for the current year.

An institutional investor recently raised its position in Edap Tms stock. Archon Capital Management LLC grew its position in shares of Edap Tms SA (NASDAQ:EDAP) by 7.5% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,019,011 shares of the medical equipment provider’s stock after buying an additional 71,336 shares during the quarter. Edap Tms accounts for 0.2% of Archon Capital Management LLC’s portfolio, making the stock its 14th largest position. Archon Capital Management LLC owned about 3.51% of Edap Tms worth $2,364,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 8.13% of the company’s stock.

Edap Tms Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company operates in two divisions: High Intensity Focused Ultrasound (HIFU), and Urology Devices and Services (UDS).

Featured Article: Leveraged Buyout (LBO)

Get a free copy of the Zacks research report on Edap Tms (EDAP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Edap Tms Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edap Tms and related companies with MarketBeat.com's FREE daily email newsletter.